$TRUG
Trugolf Holdings Inc Stock $trug

$trug Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000149315223019509 Filed on May 31, 2023

Income Statement

Concept	2023 Q1	2023	2022
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue	$1.142M
YoY Change
Gross Profit	$3.941M
YoY Change
Gross Profit Margin
Selling, General & Admin	$764.2K	$2.167M	$409.9K
YoY Change	331.68%	428.68%	590.08%
% of Gross Profit	19.39%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$10.34K
YoY Change
% of Gross Profit	0.26%
Operating Expenses	$764.2K	$2.167M	$409.9K
YoY Change	331.68%	428.68%	590.08%
Operating Profit	-$4.905M
YoY Change
Interest Expense	$95.76K	$1.824M	-$4.130K
YoY Change	-1615.19%	-44275.79%
% of Operating Profit
Other Income/Expense, Net	-$446.7K	$1.824M	-$4.133K
YoY Change		-44243.7%
Pretax Income	-$668.5K	$274.1K	-$414.1K
YoY Change	264.58%	-166.21%	597.05%
Income Tax	-$10.85K	$57.57K	$0.00
% Of Pretax Income		21.0%
Net Earnings	-$657.6K	-$400.2K	-$414.1K
YoY Change	258.66%	-3.34%	597.05%
Net Earnings / Revenue
Basic Earnings Per Share	-$446.20
Diluted Earnings Per Share	-$0.14	-$0.03	-$25.20K
COMMON SHARES
Basic Shares Outstanding	11.99K shares
Diluted Shares Outstanding	11.99K shares

Balance Sheet

Concept	2023 Q1	2023	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$9.756M	$9.756M	$128.6M
YoY Change	-92.42%	-92.42%	25623.99%
Cash & Equivalents	$595.5K
Short-Term Investments	$9.161M	$9.161M	$127.8M
Other Short-Term Assets	$20.41K	$20.41K	$315.3K
YoY Change	-93.53%	-93.53%	740.83%
Inventory
Prepaid Expenses	$20.41K
Receivables
Other Receivables
Total Short-Term Assets	$9.777M	$9.777M	$129.0M
YoY Change	-92.42%	-92.42%	23888.18%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$0.00	$0.00	$0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets	$9.777M	$9.777M	$129.0M
Total Long-Term Assets	$0.00	$0.00	$0.00
Total Assets	$9.777M	$9.777M	$129.0M
YoY Change	-92.42%	-92.42%	23888.18%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses	$866.5K	$872.5K	$36.71K
YoY Change	5414.89%	2276.74%	-10.16%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$1.865M	$1.865M	$500.0K
YoY Change	273.0%	273.0%
Total Short-Term Liabilities	$2.795M	$2.795M	$536.7K
YoY Change	420.78%	420.78%	1210.33%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$4.428M	$4.428M	$4.428M
YoY Change	0.0%	0.0%	73691.67%
Total Long-Term Liabilities	$4.428M	$4.428M	$4.428M
YoY Change	0.0%	0.0%	775.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.795M	$2.795M	$536.7K
Total Long-Term Liabilities	$4.428M	$4.428M	$4.428M
Total Liabilities	$7.223M	$7.223M	$4.964M
YoY Change	45.49%	45.49%	807.6%
SHAREHOLDERS EQUITY
Retained Earnings	-$6.441M
YoY Change	70.55%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$6.440M	$2.554M	$124.0M
YoY Change
Total Liabilities & Shareholders Equity	$9.777M	$9.777M	$129.0M
YoY Change	-92.42%	-92.42%	23888.18%

Cashflow Statement

Concept	2023 Q1	2023	2022
OPERATING ACTIVITIES
Net Income	-$657.6K	-$400.2K	-$414.1K
YoY Change	258.66%	-3.34%	597.05%
Depreciation, Depletion And Amortization	$10.34K
YoY Change
Cash From Operating Activities	-$366.6K	-$1.036M	-$697.9K
YoY Change	266.27%	48.51%	1294.9%
INVESTING ACTIVITIES
Capital Expenditures	$46.65K
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$120.9M	$120.4M	-$127.8M
YoY Change		-194.25%
Cash From Investing Activities	$120.9M	$120.4M	-$127.8M
YoY Change		-194.25%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change			-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-120.9M	-$119.7M	128.8M
YoY Change		-192.88%	23321.18%
NET CHANGE
Cash From Operating Activities	-366.6K	-$1.036M	-697.9K
Cash From Investing Activities	120.9M	$120.4M	-127.8M
Cash From Financing Activities	-120.9M	-$119.7M	128.8M
Net Change In Cash	-366.6K	-$281.6K	377.0K
YoY Change	266.27%	-174.68%	-24.6%
FREE CASH FLOW
Cash From Operating Activities	-$366.6K	-$1.036M	-$697.9K
Capital Expenditures	$46.65K
Free Cash Flow	-$413.3K
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001857086
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022Q1	us-gaap	Taxes Payable Current TaxesPayableCurrent		usd
CY2023Q1	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues		usd
CY2022	DMAQ	Stock Issued During Period Value Reclassification From Negative Additional Paidin Capital To Accumulated Deficit StockIssuedDuringPeriodValueReclassificationFromNegativeAdditionalPaidinCapitalToAccumulatedDeficit		usd
CY2023	DMAQ	Stock Issued During Period Value Conversion From Class B To Class A StockIssuedDuringPeriodValueConversionFromClassBToClassA		usd
CY2022	us-gaap	Increase Decrease In Accrued Taxes Payable IncreaseDecreaseInAccruedTaxesPayable		usd
CY2022	DMAQ	Distribution For Taxes Payments DistributionForTaxesPayments		usd
CY2022	DMAQ	Cash Released From Trust Account CashReleasedFromTrustAccount		usd
CY2022	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt		usd
CY2022	DMAQ	Cash Used For Common Stock Redemption CashUsedForCommonStockRedemption		usd
CY2023	DMAQ	Proceeds From Sale Of Units Net Of Underwriting Discounts Paid ProceedsFromSaleOfUnitsNetOfUnderwritingDiscountsPaid		usd
CY2023	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement		usd
CY2023	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts		usd
CY2023	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt		usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2023	us-gaap	Noncash Or Part Noncash Acquisition Investments Acquired1 NoncashOrPartNoncashAcquisitionInvestmentsAcquired1		usd
CY2023	DMAQ	Deferred Underwriting Fee Payable DeferredUnderwritingFeePayable		usd
CY2023	DMAQ	Additional Shares Issued To Sponsor Due To Upsize Of Ipo AdditionalSharesIssuedToSponsorDueToUpsizeOfIpo		usd
CY2022	DMAQ	Reclassification Of Class Common Stock ReclassificationOfClassCommonStock		usd
CY2022	DMAQ	Remeasurement For Class Common Stock Subject To Possible Redemption RemeasurementForClassCommonStockSubjectToPossibleRedemption		usd
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--03-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-40970
CY2023	dei	Entity Registrant Name EntityRegistrantName	Deep Medicine Acquisition Corp.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	85-3269086
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	595 Madison Avenue
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	12th Floor
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	New York
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1333482	usd
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10017
CY2023	dei	City Area Code CityAreaCode	(917)
CY2023	dei	Local Phone Number LocalPhoneNumber	289-2776
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	true
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2022Q3	dei	Entity Public Float EntityPublicFloat	127385500	usd
CY2023	dei	Auditor Firm AuditorFirmId	206
CY2023	dei	Auditor Name AuditorName	MaloneBailey, LLP
CY2023	dei	Auditor Location AuditorLocation	Houston, Texas
CY2023Q1	us-gaap	Cash Cash	595536	usd
CY2022Q1	us-gaap	Cash Cash	877099	usd
CY2023Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	20408	usd
CY2022Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	315306	usd
CY2023Q1	us-gaap	Assets Held In Trust Current AssetsHeldInTrustCurrent	9160803	usd
CY2022Q1	us-gaap	Assets Held In Trust Current AssetsHeldInTrustCurrent	127760867	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	9776747	usd
CY2022Q1	us-gaap	Assets Current AssetsCurrent	128953272	usd
CY2023Q1	us-gaap	Assets Assets	9776747	usd
CY2022Q1	us-gaap	Assets Assets	128953272	usd
CY2023Q1	DMAQ	Accrued Liabilities Related Party Current AccruedLiabilitiesRelatedPartyCurrent	6000	usd
CY2022Q1	DMAQ	Accrued Liabilities Related Party Current AccruedLiabilitiesRelatedPartyCurrent	21000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	866500	usd
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	15712	usd
CY2023Q1	us-gaap	Taxes Payable Current TaxesPayableCurrent	57569	usd
CY2023Q1	us-gaap	Loans Payable Current LoansPayableCurrent	1865000	usd
CY2022Q1	us-gaap	Loans Payable Current LoansPayableCurrent	500000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	2795069	usd
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	536712	usd
CY2023Q1	us-gaap	Deferred Compensation Liability Classified Noncurrent DeferredCompensationLiabilityClassifiedNoncurrent	4427500	usd
CY2022Q1	us-gaap	Deferred Compensation Liability Classified Noncurrent DeferredCompensationLiabilityClassifiedNoncurrent	4427500	usd
CY2023Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	4427500	usd
CY2022Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	4427500	usd
CY2023Q1	us-gaap	Liabilities Liabilities	7222569	usd
CY2022Q1	us-gaap	Liabilities Liabilities	4964212	usd
CY2023Q1	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	830210	shares
CY2023Q1	us-gaap	Temporary Equity Redemption Price Per Share TemporaryEquityRedemptionPricePerShare	10.90
CY2022Q1	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	12650000	shares
CY2022Q1	us-gaap	Temporary Equity Redemption Price Per Share TemporaryEquityRedemptionPricePerShare	10.10
CY2023Q1	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	8994434	usd
CY2022Q1	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	127765000	usd
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2022Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-6440634	usd
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-3776318	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-6440256	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-3775940	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	9776747	usd
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	128953272	usd
CY2023	us-gaap	Officers Compensation OfficersCompensation	60000	usd
CY2022	us-gaap	Officers Compensation OfficersCompensation	60000	usd
CY2023	DMAQ	Franchise Taxes FranchiseTaxes	200000	usd
CY2022	DMAQ	Franchise Taxes FranchiseTaxes	1177	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1907122	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	348735	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	2167122	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	409912	usd
CY2023	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	1824459	usd
CY2022	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-4133	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1824459	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4133	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Interest Expense Interest Income Income Taxes Extraordinary Items Noncontrolling Interests Net IncomeLossFromContinuingOperationsBeforeInterestExpenseInterestIncomeIncomeTaxesExtraordinaryItemsNoncontrollingInterestsNet	-342663	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Interest Expense Interest Income Income Taxes Extraordinary Items Noncontrolling Interests Net IncomeLossFromContinuingOperationsBeforeInterestExpenseInterestIncomeIncomeTaxesExtraordinaryItemsNoncontrollingInterestsNet	-414045	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	57569	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-400232	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-414045	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	-9395	usd
CY2022	DMAQ	Stock Issued During Period Value In Ipo StockIssuedDuringPeriodValueInIPO	126500000	usd
CY2022	DMAQ	Adjustments To Additional Paid In Capital Offering Cost AdjustmentsToAdditionalPaidInCapitalOfferingCost	2855000	usd
CY2022	DMAQ	Adjustments To Additional Paid In Capital Deferred Underwriting Commission AdjustmentsToAdditionalPaidInCapitalDeferredUnderwritingCommission	4427500	usd
CY2022	DMAQ	Stock Issued During Period Value Sale Of Private Units StockIssuedDuringPeriodValueSaleOfPrivateUnits	5195000	usd
CY2022	DMAQ	Stock Issued During Period Value Common Stock Possible Redemption StockIssuedDuringPeriodValueCommonStockPossibleRedemption	-127765000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-414045	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-3775940	usd
CY2023	us-gaap	Stock Redeemed Or Called During Period Value StockRedeemedOrCalledDuringPeriodValue	-2264084	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-400232	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-6440256	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-400232	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-414045	usd
CY2023	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	1824459	usd
CY2022	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-4133	usd
CY2023	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-294898	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	277806	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	850788	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	14850	usd
CY2023	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	-15000	usd
CY2022	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	-25000	usd
CY2023	us-gaap	Increase Decrease In Accrued Taxes Payable IncreaseDecreaseInAccruedTaxesPayable	57569	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1036436	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-697868	usd
CY2023	DMAQ	Distribution For Taxes Payments DistributionForTaxesPayments	754873	usd
CY2023	DMAQ	Cash Released From Trust Account CashReleasedFromTrustAccount	121034650	usd
CY2023	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	1365000	usd
CY2022	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	127765000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	120424523	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-127765000	usd
CY2023	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	1365000	usd
CY2023	DMAQ	Cash Used For Common Stock Redemption CashUsedForCommonStockRedemption	121034650	usd
CY2022	DMAQ	Proceeds From Sale Of Units Net Of Underwriting Discounts Paid ProceedsFromSaleOfUnitsNetOfUnderwritingDiscountsPaid	123970000	usd
CY2022	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	5195000	usd
CY2022	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	325000	usd
CY2022	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	100	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-119669650	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	128839900	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-281563	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	377032	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	877099	usd
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	500067	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	595536	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	877099	usd
CY2022	us-gaap	Noncash Or Part Noncash Acquisition Investments Acquired1 NoncashOrPartNoncashAcquisitionInvestmentsAcquired1	127765000	usd
CY2022	DMAQ	Deferred Underwriting Fee Payable DeferredUnderwritingFeePayable	4427500	usd
CY2022	DMAQ	Additional Shares Issued To Sponsor Due To Upsize Of Ipo AdditionalSharesIssuedToSponsorDueToUpsizeOfIpo	28	usd
CY2023	DMAQ	Reclassification Of Class Common Stock ReclassificationOfClassCommonStock	316	usd
CY2023	DMAQ	Remeasurement For Class Common Stock Subject To Possible Redemption RemeasurementForClassCommonStockSubjectToPossibleRedemption	2264084	usd
CY2021Q4	DMAQ	Transaction Costs TransactionCosts	7282500	usd
CY2021Q4	DMAQ	Underwriting Commission UnderwritingCommission	2530000	usd
CY2021Q4	DMAQ	Marketing Fee MarketingFee	4427500	usd
CY2021Q4	DMAQ	Offering Costs OfferingCosts	325000	usd
CY2021Q4	us-gaap	Assets Held In Trust AssetsHeldInTrust	127765000	usd
CY2021Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	10.10
CY2021Q4	DMAQ	Investment Maturity Days InvestmentMaturityDays	P185D
CY2021Q4	us-gaap	Cash Cash	764101	usd
CY2023Q1	us-gaap	Cash Cash	595536	usd
CY2023Q1	DMAQ	Working Capital WorkingCapital	2179125	usd
CY2022Q4	DMAQ	Percentage Of Outstanding Public Shares PercentageOfOutstandingPublicShares	1	pure
CY2022Q4	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	50000	usd
CY2022Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	10.10
CY2023Q1	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	830210	shares
CY2021Q4	DMAQ	Business Combination Description BusinessCombinationDescription	In addition, under a business combination marketing agreement, the Company has engaged I-Bankers as an advisor in connection with the Business Combination and will pay I-Bankers a cash fee for such marketing services upon the consummation of the Business Combination in an amount equal to, in the aggregate, 3.5% of the gross proceeds of the IPO, including any proceeds from the exercise of the underwriters’ over-allotment option
CY2023	us-gaap	Basis Of Accounting BasisOfAccounting	<p id="xdx_84A_eus-gaap--BasisOfAccounting_zSnCUAPu378j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zhB17acdplTj">Basis of Presentation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying financial statements are presented in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and pursuant to the rules and regulations of US Securities and Exchange Commission (“SEC”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84B_eus-gaap--UseOfEstimates_ze9skrCqjEF6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_861_z4kkO6Blw735">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statement and the reported amounts of expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statement, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q1	us-gaap	Cash Cash	595536	usd
CY2023	DMAQ	Distribution For Taxes Payments From The Trust Account DistributionForTaxesPaymentsFromTheTrustAccount	554873	usd
CY2022Q1	us-gaap	Cash Cash	877099	usd
CY2023Q1	us-gaap	Assets Held In Trust Current AssetsHeldInTrustCurrent	9160803	usd
CY2022Q1	us-gaap	Assets Held In Trust Current AssetsHeldInTrustCurrent	127760867	usd
CY2022	DMAQ	Gross Proceeds Common Stock Subject To Possible Redemption GrossProceedsCommonStockSubjectToPossibleRedemption	126500000	usd
CY2022	DMAQ	Common Stock Issuance Costs Common Stock Subject To Possible Redemption CommonStockIssuanceCostsCommonStockSubjectToPossibleRedemption	2855000	usd
CY2022	DMAQ	Remeasurement Of Carrying Value To Redemption Value Common Stock Subject To Possible Redemption RemeasurementOfCarryingValueToRedemptionValueCommonStockSubjectToPossibleRedemption	4120000	usd
CY2022Q1	DMAQ	Common Stock Subject To Possible Redemption CommonStockSubjectToPossibleRedemption	127765000	usd
CY2023	DMAQ	Distribution For Redemption DistributionForRedemption	121034650	usd
CY2023	DMAQ	Remeasurement Of Carrying Value To Redemption Value RemeasurementOfCarryingValueToRedemptionValue	2264084	usd
CY2023Q1	DMAQ	Common Stock Subject To Possible Redemption CommonStockSubjectToPossibleRedemption	8994434	usd
CY2023	DMAQ	Representative Warrants Issued RepresentativeWarrantsIssued	101200	shares
CY2023Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	632500	shares
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	274139	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	57569	usd
CY2023Q1	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	0	usd
CY2022Q1	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	0	usd
CY2023Q1	us-gaap	Operating Loss Carryforwards Valuation Allowance OperatingLossCarryforwardsValuationAllowance	0	usd
CY2022Q1	us-gaap	Operating Loss Carryforwards Valuation Allowance OperatingLossCarryforwardsValuationAllowance	0	usd
CY2023Q1	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	0	usd
CY2022Q1	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	0	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-400232	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-414045	usd
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_848_eus-gaap--ConcentrationRiskCreditRisk_z1j2QbE5u3z9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_861_zC5yMqmsG245">Concentration of Credit Risk</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times may exceed the Federal Depository Insurance Coverage of $<span id="xdx_904_eus-gaap--FederalDepositInsuranceCorporationPremiumExpense_c20220401__20230331_ziJd05MEWHY4" title="Federal depository insurance">250,000</span>. The Company has not experienced losses on these accounts.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023	us-gaap	Federal Deposit Insurance Corporation Premium Expense FederalDepositInsuranceCorporationPremiumExpense	250000	usd
CY2023Q1	DMAQ	Accrued Liabilities Related Party Current AccruedLiabilitiesRelatedPartyCurrent	6000	usd
CY2022Q1	DMAQ	Accrued Liabilities Related Party Current AccruedLiabilitiesRelatedPartyCurrent	21000	usd
CY2023Q1	DMAQ	Accrued Non Cash Compensation AccruedNonCashCompensation	6000	usd
CY2023Q1	us-gaap	Share Price SharePrice	0.02
CY2023Q1	DMAQ	Working Capital Loans WorkingCapitalLoans	1500000	usd
CY2023Q1	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	10.00
CY2023Q1	DMAQ	Working Capital Loans Outstanding WorkingCapitalLoansOutstanding	0	usd
CY2022Q1	DMAQ	Working Capital Loans Outstanding WorkingCapitalLoansOutstanding	0	usd
CY2021Q4	us-gaap	Share Price SharePrice	0.20
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	830210	shares
CY2023	DMAQ	Warrants Exercise Price Per Share WarrantsExercisePricePerShare	12.00
CY2023Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	2.11
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.35	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0118	pure
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2023	DMAQ	Representative Warrants Shares Days RepresentativeWarrantsSharesDays	P180D

Files In Submission

Name	View Source	Status
0001493152-23-019509-index-headers.html	Edgar Link	pending
0001493152-23-019509-index.html	Edgar Link	pending
0001493152-23-019509.txt	Edgar Link	pending
0001493152-23-019509-xbrl.zip	Edgar Link	pending
dmaq-20230331.xsd	Edgar Link	pending
ex21.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
ex4-6.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
dmaq-20230331_cal.xml	Edgar Link	unprocessable
dmaq-20230331_def.xml	Edgar Link	unprocessable
dmaq-20230331_lab.xml	Edgar Link	unprocessable
dmaq-20230331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
form10-k_htm.xml	Edgar Link	completed
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TRUG
Trugolf Holdings Inc Stock $trug

2023 Q1 Form 10-K Financial Statement

#000149315223019509 Filed on May 31, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TRUG Trugolf Holdings Inc Stock $trug

2023 Q1 Form 10-K Financial Statement

#000149315223019509 Filed on May 31, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TRUG
Trugolf Holdings Inc Stock $trug